RiboX Therapeutics Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RXRG001 for the Treatment of Radiation-Induced Xerostomia and Hyposalivation

RiboX Therapeutics received FDA Regenerative Medicine Advanced Therapy (RMAT) designation for RXRG001, its treatment candidate for radiation-induced xerostomia and hyposalivation. The designation may expedite development and regulatory engagement for the therapy, representing a positive clinical and regulatory milestone for the company.